Common Antibiotic Mechanism Shown

Researchers from the University of Boston and MIT have reported that guanine oxidation is at the heart of the cell-killing abilities of many common antibiotics. The findings, published recently in the journal Science, if confirmed, could improve scientists’ understanding of the way existing antibiotics actually work. Previously, James J. Collins and coworkers at Boston University reported that diverse antibiotics with different targets have a common cell-killing mechanism. They discovered that various antibiotics trigger the production of hydroxyl radicals, leading to oxidative damage and cell death, but they didn’t describe the process in detail. Now, Graham C. Walker of MIT and colleagues have teamed up with Collins’ group to show that a specific type of oxidative damage, guanine oxidation, is the main cause of cell death by bactericidal antibiotics. In this process, hydroxyl radicals oxidise the DNA base guanine to form 7, 8-dihydro-8-oxoguanine, or 8-oxoguanine. Cells deal with 8-oxoguanine by excising and replacing the base in DNA, but those defences can be overwhelmed by too much 8-oxoguanine. If the modified bases occur too often and too close together, the repair mechanism instead breaks the DNA strand. The accumulation of these breaks leads to cell death. Walker and Collins’ team treated Escherichia coli cells with different classes of antibiotics: a ?-lactam (ampicillin), a quinolone (norfloxacin), and an amino­glycoside (kanamycin). By adjusting the expression of enzymes in cells’ guanine oxidation defence mechanism, the researchers showed that the bacteria became less sensitive to antibiotics when expression increased and more sensitive when expression decreased. “Hydroxyl radicals are not only extremely reactive but also very nondiscriminatory in their reactions,” Walker says. “There was no particular a priori reason to suspect that oxidation of one very particular type of biomolecule was particularly responsible for cell death.” The findings suggest that the usefulness of current drugs to treat bacterial infections could be extended with adjuvants that target the guanine oxidation pathway, the researchers write. “The work is certainly interesting and thought-provoking,” says Shahriar Mobashery, an antibiotics expert at the University of Notre Dame. “No doubt its generality with other antibiotics, beyond the three classes that have been looked at, will be investigated in the coming weeks and months.”

Chemical & Engineering News, 23 April 2012 ; ;